Eli Lilly plans to launch two new cheaper insulin products amid criticism about the availability of its lower-cost insulins on pharmacy shelves.
Lilly is planning to offer lower-priced versions of its Humalog Mix75/25 KwikPen (insulin lispro protamine and insulin lispro injectable suspension 100 units/mL) and Humalog Junior KwikPen (insulin lispro injection 100 units/mL).
“Both insulins will have 50 percent lower list prices compared to the branded versions and will be available by mid-April,” the company said, adding that both products will be sold in five-packs at a list price of $265.20.
The company came under fire from lawmakers in December over the generic Humalog product it launched last year. Sens. Elizabeth Warren (D-Mass.) and Richard Blumenthal (D-Conn.) claimed that the insulin was “inaccessible” in a majority of U.S. pharmacies.